Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
| Status: | Completed |
|---|---|
| Conditions: | Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/17/2017 |
| Start Date: | April 2015 |
| End Date: | July 2017 |
UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Photodynamic therapy is an effective treatment for actinic keratoses. In the United States
topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment,
and it has traditionally been activated with the use of an in-office artificial light source.
This clinical trial seeks to measure the safety and efficacy of using natural sunlight to
activate the ALA.
topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment,
and it has traditionally been activated with the use of an in-office artificial light source.
This clinical trial seeks to measure the safety and efficacy of using natural sunlight to
activate the ALA.
- Initial Visit:
- study inclusion criteria reviewed
- consent forms reviewed
- creation of facial map for actinic keratoses
- face cleansed with chlorhexidine soap
- light curettage of precancerous skin lesions
- application of topical aminolevulinic acid (ALA)
- application of sunscreen
- patient then spends 2 hours outdoors in a shaded area
- after treatment the patient is to remain indoors for 48 hours
- 3 month follow up visit
- facial map of actinic keratoses used to document treatment response
- 6 month follow up visit
- facial map of actinic keratoses used to document treatment response
- study inclusion criteria reviewed
- consent forms reviewed
- creation of facial map for actinic keratoses
- face cleansed with chlorhexidine soap
- light curettage of precancerous skin lesions
- application of topical aminolevulinic acid (ALA)
- application of sunscreen
- patient then spends 2 hours outdoors in a shaded area
- after treatment the patient is to remain indoors for 48 hours
- 3 month follow up visit
- facial map of actinic keratoses used to document treatment response
- 6 month follow up visit
- facial map of actinic keratoses used to document treatment response
Inclusion Criteria:
- Clinical diagnosis of >10 actinic keratoses on head and neck
- Age ≥ 18 years (Because no dosing or adverse event data are currently available on the
use of topical aminolevulinic acid in patients <18 years of age, children are excluded
from this study)
- Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria:
- Patients currently undergoing anti-neoplastic therapy including but not limited to the
following:
- Topical imiquimod
- Topical 5-fluorouracil
- Topical ingenol mebutate
- Topical diclofenac
- Topical retinoids
- Oral acitretin
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to aminolevulinic acid
- Patients with a known photosensitivity disorder including but not limited to
porphyria, lupus, polymorphous light eruption, or immunobullous disease.
- Patients taking known photosensitizing medications including but not limited to
griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and
tetracyclines.
- pregnancy
We found this trial at
1
site
University of California, Irvine Since 1965, the University of California, Irvine has combined the strengths...
Click here to add this to my saved trials
